Fresh analysis reveals that individuals who stop using new GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who stop traditional lifestyle regimens.
Findings released in a prominent health publication shows that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month after stopping.
"Users buying such treatments should be aware of the potential of rapid rebound weight gain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to original weight in about 18 months.
Analyzing Treatments
The study, which looked at 37 of studies involving over 9,000 of participants, contrasted the effects of the injectable medications with older methods.
The team point out that people who shed pounds through dieting usually have a less rapid creep back—around 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Nutrition scientists propose the way of the jabs explains the accelerated regain.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this medication leads to hunger is uncontrolled, making binge eating a significant risk."
A Chronic Condition?
The NHS recommend the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.
Professionals say that, considering the significant potential of weight regain, the treatment should be considered long-term.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the chronic character of obesity," akin to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication report a intense return of hunger.
"It was like something activating and you become starving," said an individual.
The struggle is worsened if patients have not adopted lasting lifestyle or habit modifications during therapy.
Significant Use
Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is more common among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while these medications are powerful agents for weight loss, they are not a magic solution and maintained weight loss relies on combined behavioural management.
